Scilex Holding (SCLX) Non-Current Deffered Revenue (2021 - 2026)
Scilex Holding (SCLX) posted quarterly Non-Current Deffered Revenue of $1.9 million for Q1 2026, down 16.99% year-over-year from $2.3 million in Q1 2025, and down 4.7% quarter-over-quarter from $2.0 million in Q4 2025.
Scilex Holding (SCLX) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends
Scilex Holding's Non-Current Deffered Revenue history runs 6 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 16.99% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 16.99% YoY), while the FY2025 annual figure was $2.0 million, down 16.63% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $1.9 million, down from $2.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $5.2 million in Q1 2022, with the low at $1.9 million in Q1 2026.
- The 5-year median for Non-Current Deffered Revenue is $2.8 million (2024), against an average of $3.1 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue changed 0.0% in 2022, then slumped 41.93% in 2023.
- Scilex Holding's Non-Current Deffered Revenue stood at $3.4 million in 2022, then dropped by 14.53% to $2.9 million in 2023, then fell by 15.44% to $2.4 million in 2024, then dropped by 16.63% to $2.0 million in 2025, then declined by 4.7% to $1.9 million in 2026.
- Business Quant data shows SCLX's Non-Current Deffered Revenue at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn | 1.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.95 Mn |
| Dec 31, 2025 | 2.04 Mn |
| Sep 30, 2025 | 2.14 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 2.34 Mn |
| Dec 31, 2024 | 2.45 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 2.67 Mn |
| Mar 31, 2024 | 2.78 Mn |
| Dec 31, 2023 | 2.90 Mn |
| Sep 30, 2023 | 3.01 Mn |
| Jun 30, 2023 | 3.14 Mn |
| Mar 31, 2023 | 3.26 Mn |
| Dec 31, 2022 | 3.39 Mn |
| Sep 30, 2022 | 5.19 Mn |
| Jun 30, 2022 | 5.19 Mn |
| Mar 31, 2022 | 5.19 Mn |
| Sep 30, 2021 | 5.19 Mn |
| Jun 30, 2021 | 5.19 Mn |
| Mar 31, 2021 | 5.19 Mn |